List Biotherapeutics, a venture under Genome and Company, has announced plans to build a manufacturing facility at the Fishers Life Science & Innovation Park in Indiana, following the close of a Series A round investment.
The company raised $31m in Series A financing in December 2021 followed by a second tranche of $17.4m in March 2022. Upon completion of the facility, List Bio, together with List Labs, will offer end-to-end manufacturing for early-stage development through commercial production of microbiome therapeutics, the company says.
The 110,000 sqft contract manufacturing facility will create hundreds of jobs in the city of Fishers, the company says.
Jisoo Pae, founder & CEO of Genome and Company, said: “I am grateful to the investors who believed in the growth potential of our microbiome CDMO business. We will develop new microbiome therapeutics and kick-start the new business as part of our aim to lead the way as the distinguishing microbiome biotech with a fully integrated pharmaceutical value chain.”
The Fishers Life Science & Innovation Park was established in August 2021 and has seen more than $200m in investment from life science firms Stevanato Group and INCOG Pharma. List Bio will contribute a further $125 million with the project.